1 / 25

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation. Genetics PCSK9. PCSK9-Directed Therapies in Development. Alirocumab (SAR236553) Change in LDL-C at 2- and 4-Week Dosing Intervals on Atorvastatin.

oren-knox
Download Presentation

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation

  2. Genetics PCSK9

  3. PCSK9-Directed Therapies in Development

  4. Alirocumab (SAR236553)Change in LDL-C at 2- and 4-Week Dosing Intervals on Atorvastatin

  5. Evolocumab (AMG 145) Change in LDL-C at 2- and 4-Week Dosing Intervals on Statin Therapy

  6. MENDELEvolocumab Monotherapy for Hypercholesterolemia

  7. LAPLACE-TIMI 57Evolocumab Combined With Statin for Hypercholesterolemia

  8. StatinsApproximate LDL-C Lowering Efficacy

  9. ENHANCESimvastatin/Ezetimibe in FH

  10. Effect of Alirocumab on LDL-C in Heterozygous FH

  11. RUTHERFORDEffect of Evolocumab on LDL-C in Heterozygous FH

  12. GAUSSEvolocumab in Statin Intolerance

  13. PCSK9-Directed Therapies in Development

  14. OSLER Extension Study

  15. OSLEREffect of Evolocumab on LDL-C after 52 Weeks

  16. Clinical Utility of PCSK9 Inhibitors

  17. Phase 3 Trials

  18. Use of PCSK9 InhibitorsBased on Evidence or Definitive Outcomes Data?

  19. Abbreviations

  20. Abbreviations (cont)

  21. References

  22. References (cont)

  23. References (cont)

More Related